Neurology
-
How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation
Breaking down the FDA-approved sublingual film’s mechanism, trial statistics, and accessibility for patients managing acute agitation at home.
-
Study Finds Autistic Adults Over 45 Face Nearly Triple Parkinsonism Rates
A U.S. Medicare analysis shows Parkinsonism prevalence of 3.8% in autistic seniors versus 1.6% in peers, highlighting new neurodegenerative risks for the…
-
Generalized Myasthenia Gravis: Autoimmune Attack on Nerve-Muscle Junction Causes Progressive Weakness
Generalized myasthenia gravis is an autoimmune disorder where antibodies destroy acetylcholine receptors, leading to muscle weakness that worsens with activity and improves…
-
FDA Approves Zanvastro, the First Drug for the Rare Brain Disorder Alexander Disease
Madison, October 16 — The US Food and Drug Administration has approved Zanvastro, the first drug designed to directly treat Alexander disease,…
-
Lecanemab and Donanemab: Biology of Amyloid-Targeting Drugs
ISLAMABAD, July 8 — For decades, the sticky clumps of protein that build up in the brains of Alzheimer’s patients have been…
-
Grey Hair in Your 20s, Foggy Memory in Your 30s: What Neurologists Say About Stress
MANILA, June 28 — For many people across Asia, noticing grey hair in their twenties or struggling with memory in their thirties…
-
Neurologists say grey hair and memory lapses do not necessarily mean faster aging
MANILA — The grey hair in your 20s. The forgotten appointment at 35. For millions across Asia, these moments trigger a private…
-
FDA Approves Vertex’s Journavx, the First New Class of Pain Medicine in Over 20 Years
Vertex Pharmaceuticals is awaiting a regulatory decision on suzetrigine, a non-opioid analgesic designed for moderate to severe acute pain. The drug, which…
-
American Headache Society Endorses CGRP Antagonists for Migraines
On March 11, 2024, the American Headache Society issued a statement that underscores the evolving landscape of migraine treatment, highlighting the emergence…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
New Studies Show Immunotherapy Gaining Ground in Lung, Prostate and Childhood Cancers
-
Why Broad RAS-Targeting Drugs Mark a Turning Point in Treating Pancreatic Cancer
-
How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation
-
Boron Neutron Capture Therapy Faces US Coverage Hurdles Over Cost and Data Gaps
-
FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653
-
Biocon’s Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992









